Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35,322 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: alone Clear all
Completed Phase 1 Interventional

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
EOS789, Placebo, Renvela
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

NCT01476137
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK2110183
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Results available

Tdap Vaccine in Post-Partum Women

NCT01711645
View directory record Official record
Conditions
Diphtheria, Pertussis, Tetanus
Interventions
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions

NCT00727272
View directory record Official record
Conditions
Healthy
Interventions
Quinine Sulfate Capsules 324 mg, Quinine Sulphate Tablets 300 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Toward Zero Prescribed Opioids for Outpatient General Surgery

NCT05327777
View directory record Official record
Conditions
Opioid Misuse and Addiction, Pain
Interventions
Oxycodone, Zero Opioid Protocol
Drug · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 99 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 29, 2026, 4:20 PM EDT
Recruiting Phase 4 Interventional

Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System

NCT04279457
View directory record Official record
Conditions
AKI (Acute Kidney Injury) Due to Trauma
Interventions
DyeVert Plus System, Standardized hydration protocol
Device · Other
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
1,802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

NCT00126581
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Erlotinib, Erlotinib Hydrochloride, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
96
States / cities
Castro Valley, California • Emeryville, California • Fremont, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 29, 2026, 4:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Methods for Assessing Intraocular Lens Position

NCT07218419
View directory record Official record
Conditions
Tilt and Decentration
Interventions
IOL Decentration Assessment
Diagnostic Test
Lead sponsor
Johnson & Johnson Surgical Vision, Inc.
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Bakersfield, California • Sioux City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 29, 2026, 4:20 PM EDT
Terminated No phase listed Observational

PRODIGY Registry in NYHA Class III Heart Failure Patients

NCT03623165
View directory record Official record
Conditions
Heart Failure NYHA Class III
Interventions
Cordella™ Heart Failure System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 29, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00003567
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Not applicable Interventional

Study of Provent Treatment of Obstructive Sleep Apnea in Patients Who Are Non-compliant With CPAP

NCT00901771
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Provent
Device
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Not applicable Interventional

Patient NAVIgation to Reduce Readmissions Among Black Men With Heart Disease

NCT02340364
View directory record Official record
Conditions
Heart Diseases
Interventions
Education + Patient Navigation, Self-care Education
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Bessemer, Alabama • Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00587964
View directory record Official record
Conditions
Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

NCT04863287
View directory record Official record
Conditions
Lyme Disease
Interventions
2217LS, 0.9% Sodium Chloride (NaCl)
Biological · Other
Lead sponsor
MassBiologics
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 29, 2026, 4:20 PM EDT
No Longer Available No phase listed Expanded access

Compassionate Use Treatment for a Single Patient With a Custom Made Branched/Fenestrated Endovascular Device for the Treatment of Complex Abdominal Aortic Aneurysm

NCT03159858
View directory record Official record
Conditions
Complex Abdominal Aortic Aneurysm
Interventions
Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
70 Years to 70 Years · Male only
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Straumann Roxolid Multi-Center Study

NCT01842958
View directory record Official record
Conditions
Jaw, Edentulous, Partially
Interventions
Straumann Bone Level Implants, 4.1 mm implant diameter, Straumann Bone Level Implants, 3.3 mm implant diameter
Device
Lead sponsor
Institut Straumann AG
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Not applicable Interventional

Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device

NCT05592548
View directory record Official record
Conditions
Rosacea, Papulopustular
Interventions
cold atmospheric plasma
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

NCT03075826
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
SGI-110
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 29, 2026, 4:20 PM EDT
Completed No phase listed Observational

A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications

NCT02830178
View directory record Official record
Conditions
Hemorrhage, Gastrointestinal, Myocardial Infarction, Stroke, Kidney Diseases
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
144,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma

NCT00786643
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-Fluorouracil, Leucovorin (LV), Gamma-Interferon-1b (IFN-γ), Bevacizumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 29, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

NCT01639508
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

NCT05110976
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
18
States / cities
Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Multi-center, Single-arm Study of the Auryon Laser System for Treatment of Below-the-Knee (BTK) Arteries

NCT05284240
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Auryon Laser System
Device
Lead sponsor
Midwest Cardiovascular Research Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Miami Beach, Florida • Davenport, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 29, 2026, 4:20 PM EDT
Withdrawn Phase 1 Interventional

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

NCT01685489
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, PSK®, Docetaxel, Placebo
Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 29, 2026, 4:20 PM EDT